Immune globulin IV therapy: Optimizing care of patients in the oncology setting

Oncology Nursing Forum

Volumn 33, Issue 5, 2006, Pages 911-921

  Shelton, Brenda K ^a   Griffin, Julia M ^b   Goldman, Frederick D ^c,d,e,f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC HOSPITAL   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Pediatric Immune Disorders Clinic   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f Talecris Biotherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; CASE REPORT; HUMAN; IMMUNOLOGY; MALE; NEOPLASM; NURSE ATTITUDE; NURSING; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW;

ADULT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; NEOPLASMS; NURSE'S ROLE; PATIENT COMPLIANCE; PATIENT EDUCATION;

EID: 33750115921     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/06.ONF.911-921     Document Type: Article

References (28)

1. Brown, P. (2003). Raising nurses' awareness of primary immune deficiency. Nursing New Zealand, 9, 26-27.
2. Bussel, J.B., Eldor, A., Kelton, J.G., Varon, D., Brenner, B., Gillis, S., et al. (2004). IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thrombosis and Haemostasis, 91, 771-778.
3. Bussel, J.B., Hanna, K., & the IGIV Study Group. (2004). Intravenous immunoglobulin manufactured using a novel caprylate and chromatography-based method (IGIV-C, Gamunex®) was safe and well tolerated when administered at an increased maximum rate in patients with idiopathic thrombocytopenic purpura (ITP). Blood, 104, a632.
4. Caress, J.B., Cartwright, M.S., Donofrio, P.D., & Peacock, J.E., Jr. (2003). The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology, 60, 1822-1824.
5. Centers for Disease Control and Prevention. (1999, June). Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR: Morbidity and Mortality Weekly Report, 48, 518-521.
6. Dalakas, M.C. (1999). Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle and Nerve, 22, 1479-1497.
7. Dalakas, M.C., & Clark, W.M. (2003). Strokes, thromboembolic events, and IVIg: Rare incidents blemish an excellent safety record. Neurology, 60, 1736-1737.
8. Davis, J., Duff, K., Ganio, S., Garrow-Harris, L., Gomez, J., MacPherson, P., et al. (2003, March). Criteria for selecting an IGIV preparation: The infusion nurse's perspective. Paper presented at the 60th annual meeting of the American Academy of Allergy, Asthma, and Immunology, Denver, CO.
9. Gelfand, E.W. (2000). The clinical use of intravenous immunoglobulin in immunodeficiency and allergic disorders. Journal of Intravenous Nursing, 23(5, Suppl.), S14-S17.
10. Go, R.S., & Call, T.G. (2000). Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clinic Proceedings, 75, 83-85.
11. Gottlieb, S. (2002). Intravenous immunoglobulin increases risk of thrombotic events. BMJ, 324, 1056.
12. Griffin, J.M. (2005, April). Defining ICIV therapy: Clinical usage. Paper presented at IGIV Therapy: Optimizing Care of Patients in the Oncology Setting, Orlando, FL.
13. Grillo, J.A., Gorson, K.C., Ropper, A.H., Lewis, J., & Weinstein, R. (2001). Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology, 57, 1699-1701.
14. Hall, P.D. (1993). Immunomodulation with intravenous immunoglobulin. Pharmacotherapy, 13, 564-573.
15. Katz, K.A., Hivnor, C.M., Geist, D.E., Shapiro, M., Ming, M.E., & Werth, V.P. (2003). Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Archives of Dermatology, 139, 991-993.
16. Kazatchkine, M.D., & Kaveri, S.V. (2001). Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine, 345, 747-755.
17. Labovich, T.M. (1997). Transfusion therapy: Nursing implications. Clinical Journal of Oncology Nursing, 1, 61-72.
18. Lemm, G. (2002). Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology, 59(12, Suppl. 6), S28-S32.
19. Miller, J.L., Petteway, S.R., Jr., & Lee, D.C. (2001). Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. Journal of Allergy and Clinical Immunology, 108(4, Suppl.), S91-S94.
20. NIH consensus conference. Intravenous immunoglobulin: Prevention and treatment of disease. (1990). JAMA, 264, 3189-3193.
21. Pierce, L.R., & Jain, N. (2003). Risks associated with the use of intravenous immunoglobulin. Transfusion Medicine Reviews, 17, 241-251.
22. Ratko, T.A., Burnett, D.A., Foulke, G.E., Matuszewski, K.A., & Sacher, R.A. (1995). Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA, 273, 1865-1870.
23. Schleis, T.G. (2000). The financial, operational and clinical management of intravenous immunoglobulin administration. Journal of Intravenous Nursing, 23(5, Suppl.), S23-S31.
24. Shelton, B.K. (2005, April). Focus on use of IGIV therapy in the oncology setting. Paper presented at IGIV Therapy: Optimizing Care of Patients in the Oncology Setting, Orlando, FL.
25. Siegel, J. (2006, January). Immune globulins: Therapeutic, pharmaceutical, and cost considerations. Pharmacy Practice News, 19-23.
26. Swenson, M.R. (2000). Autoimmunity and immunotherapy. Journal of Intravenous Nursing, 23(5, Suppl.), S8-S13.
27. U.S. Food and Drug Administration. (2005). Important safety information on interference with blood glucose measurement following use of parenteral maltose/parenteral galactose/oral xylose-containing products. Retrieved June 26, 2006, from http://www.primaryimmune.org/pubs/ImportantSafetyAlert- MaltoseGalactoseOralXylose.pdf
28. Wright, J.E., & Shelton, B.K. (1993). The hematologic and immune systems. In Desk reference for critical care nursing (pp. 1073-1247). Sudbury, MA: Jones and Bartlett.